

BONESUPPORT HOLDING AB (publ) – Correction in Q3 2025 interim report

BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes a correction in the interim report for the third quarter 2025.

There was an error in the third quarter's report. In the section with non-IFRS alternative performance measures and financial definitions on page 28, an incorrect amount and growth rate have been stated for the US for the quarter's net sales at constant exchange rates (CER). The correct amount is SEK 269.6 million with a growth of 40%. The error also has a consequential effect on the table's total amount.

The correction has no effect on the report's main tables such as income statements and balance sheets and their annotations.

A corrected page is attached.

For more information contact:

BONESUPPORT Holding AB
Torbjörn Sköld, CEO
+46 (0) 46 286 53 70

Håkan Johansson, CFO
+46 (0) 46 286 53 70
ir@bonesupport.com

Cord Communications
Charlotte Stjerngren
+46 (0) 708 76 87 87
charlotte.stjerngren@cordcom.se
www.cordcom.se

About BONESUPPORT™

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform **CERAMENT**. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 899 million in 2024. Please visit www.bonesupport.com for more information.

BONESUPPORT and CERAMENT are **registered trademarks** of BONESUPPORT AB.

Press Release
31 October 2025 16:40:00 CET



Attachments

BONESUPPORT HOLDING AB (publ) – Correction in Q3 2025 interim report
BONESUPPORT Q3 2025 PAGE 28 EN